BioTuesdays

Category - Markets

Proteon Therapeutics
Markets

HCW ups Proteon Therapeutics to buy; PT $3

H.C. Wainwright upgraded Proteon Therapeutics (NASDAQ:PRTO) to “buy” from “neutral” and raised its price target to $3 from $2.30. “While investors may have written Proteon off after the failure of the PATENCY-1 study in...

May 10, 2018
TransEnterix
Markets

BTIG ups TransEnterix to buy; PT $3.50

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” with a price target of $3.50 after the company posted first quarter revenue above expectations. The stock closed at $1.83 on April 8. Dr. Sean Lavin writes that there...

May 9, 2018
IntelGenx Logo
Markets

IntelGenx closes private placement financing

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) closed a private placement of 320 units at a price of $10,000 (U.S.) a unit for gross proceeds of $3.2-million. Proceeds will be used for the company’s Montelukast Phase 2a...

May 9, 2018
CytRx
Markets

HCW analyst assumes coverage of CytRx at buy; PT $4

H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of CytRx (NASDAQ:CYTR) with a “buy” rating and price target of $4. The stock was quoted at $1.91 in afternoon trading on April 7. CytRx’s two principal value...

May 7, 2018
Cannabis Wheaton Logo
Markets

Mackie Research starts Cannabis Wheaton at buy; PT $3

Mackie Research initiated coverage of Cannabis Wheaton with a “buy” rating and $3 price target. The stock closed at $1.56 on April 2. Analyst Greg McLeish writes that Wheaton’s “unique model is made up of three distinct...

May 3, 2018
Oryzon Genomics
Markets

Roth starts Oryzon Genomics at buy; PT €15

Roth Capital Partners initiated coverage of Oryzon Genomics (ISIN Code: ES0167733015, ORY) with a “buy” rating and price target of €15. The stock was recently quoted at €2.38. “In our view, the Spanish biotech Oryzon is...

May 1, 2018
Viking Therapeutics Logo
Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018
Dova Pharmaceuticals
Markets

Ladenburg starts Dova Pharma at buy; PT $65

Ladenburg Thalmann initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and $65 price target. The stock was quoted at $26.55 near the close on April 26. Dova is focused on the development and...

April 26, 2018
Prothena
Markets

BTIG cuts Prothena to neutral; discontinues PT

BTIG downgraded Prothena (NASDAQ:PRTA) to “neutral” without a price target after the company discontinued development of NEOD001, an investigational antibody being evaluated to treat AL amyloidosis. The stock dropped...

April 24, 2018